Group items tagged

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to support screening of target-based pharmaceutical libraries to identify candidate therapeutics against select eukaryotic pathogens and subsequent preclinical development activities.

Using its strength in glycoscience, the client wishes to achieve the following FCH- and s-FCH-related goals with a potential partner to continue to supply the world with innovative pharmaceuticals/medical devices in this field: Supply pharmaceuticals/medical devices that meet unmet medical needs Specialized areas/diseases: Diseases of locomotive organs, ophthalmic diseases, and diseases of the mucous membrane in the mouth, esophagus, gastrointestinal tract, etc. Supply products that cannot be replaced by other products or competitor's products, using the client's strength in glycoscience

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to support screening of target-based pharmaceutical libraries to identify candidate therapeutics against select eukaryotic pathogens and subsequent preclinical development activities.

The Chemical and Biological Separations (CBS) program supports fundamental research on novel methods and materials for separation processes.  These processes are central to the chemical, biochemical, materials, energy, and pharmaceutical industries.  A fundamental understanding of the interfacial, transport, and thermodynamic behavior of multiphase chemical systems as well as quantitative descriptions of processing characteristics in the process-oriented industries is critical for efficient resource management and effective environmental protection.  The program encourages proposals that address emerging research areas and technologies, have a high degree of interdisciplinary thought coupled with knowledge creation, and integrate education and research.

The Chemical and Biological Separations (CBS) program supports fundamental research on novel methods and materials for separation processes.  These processes are central to the chemical, biochemical, materials, energy, and pharmaceutical industries.  A fundamental understanding of the interfacial, transport, and thermodynamic behavior of multiphase chemical systems as well as quantitative descriptions of processing characteristics in the process-oriented industries is critical for efficient resource management and effective environmental protection.  The program encourages proposals that address emerging research areas and technologies, have a high degree of interdisciplinary thought coupled with knowledge creation, and integrate education and research. Research topics OF PARTICULAR INTEREST in CBS include fundamental molecular-level work on: Nanostructured materials for separations Biorenewable resource separation processes Purification of drinking water Field (flow, magnetic, electrical) induced separations Separation of molecular constituents from blood The duration of unsolicited awards is generally one to three years.  The average annual award size for the program is $80,000.  Proposals requesting a substantially higher amount than this, without prior consultation with the Program Director, may be returned without review.  Small equipment proposals of less than $100,000 will also be considered and may be submitted during the annual submission window. 

The Beckman Center for the History of Chemistry at the Chemical Heritage Foundation (CHF), an independent research library in Philadelphia, invites applications for fellowships. Short-term fellows are particularly meant to use the collections, while long-term fellows' work must help to support the mission of the institution and fit with collections more generally. The research collections at CHF range chronologically from the fifteenth century to the present and include 6,000 rare books, significant archival holdings, thousands of images, and a large artifact and fine arts collection, supported by over 100,000 reference volumes and journals. Within the collections there are many areas of special strength, including: alchemy, mining & metallurgy, dyeing and bleaching, balneology, gunpowder and pyrotechnics, gas-lighting, books of secrets, inorganic and organic chemistry, biochemistry, food chemistry, and pharmaceuticals.

To continue making safe and effective topical semisolid drug products available to the American public, it is essential that FDA's regulatory science, as well as best practices in the pharmaceutical industry, are informed by the most current understanding of the product quality attributes that are potentially critical to the therapeutic performance of topical semisolid dosage forms. The scope of this project is to characterize all measurable physical/chemical qualities of different dosage forms of semisolid topical drug products, identify appropriate methodologies for measuring each of these quality attributes, characterize formulation and manufacturing parameters that alter the arrangement of matter in the dosage form as measured by specific quality attributes, and utilize in vitro and/or in vivo measures of product performance to correlate variations in critical quality attributes with a failure mode for a drug product.  

This Funding Opportunity Announcement (FOA) encourages applications for Countermeasures Against Chemical Threats (CounterACT) Cooperative Agreement (U01) Research Projects for research on the identification of small molecule or biologic lead compounds that are excellent candidates for therapeutic development. The mission of the CounterACT program is to foster and support research and development of new and improved therapeutics for chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pharmaceutical-based agents, and pesticides. The scope of research supported by this FOA includes confirmation of molecular targets for therapeutic development, demonstration of in vitro activity of candidate therapeutics, preliminary in vivo proof-of-concept efficacy data, preliminary adsorption, distribution, metabolism, excretion, and toxicity (ADME/Tox) evaluations and pharmacokinetics/pharmacodynamics (PK/PD) data. These studies should result in the identification of at least one lead compound ready for optimization. Lead compounds are biologically active and synthetically feasible compounds where specificity, affinity, potency, target selectivity, efficacy, and safety have been established. Lead compounds should be ready for more advanced development under possible support from other programs such as the one described in the companion FOA "CounterACT Optimization of Therapeutic Lead Compound (U01)" (PAR-18-NNN). The scope of this FOA encompasses Technical Readiness Level (TRL) 1-3 - see TRLs. Each project must include annual milestones that create discrete go or no-go decision points in a progressive translational study plan.

This Funding Opportunity Announcement (FOA) encourages applications for Countermeasures Against Chemical Threats (CounterACT) Cooperative Agreement (U01) Research Projects for research on the optimization of small molecule or biologic compounds that are excellent candidates for therapeutic development. The mission of the CounterACT Program is to foster and support research and development of new and improved therapeutics for chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pharmaceutical-based agents, and pesticides. A previously identified lead compound is required to be eligible for this funding opportunity. In this regard, lead compounds are defined as biologically active compounds or hits where affinity, potency, target selectivity, and preliminary safety have been established. The scope of research supported by this FOA includes development of appropriate human-relevant animal models and generation of in vivo efficacy data consistent with the intended use of the product in humans. It also includes bioanalytical assay development and validation, laboratory-scale and scaleable manufacturing of the product, and non-GLP toxicity and pharmacology studies. The scope of this FOA encompasses Technical Readiness Levels (TRLs) 4-5 - see TRLs. Each project must include annual milestones that create discrete go or no-go decision points in a progressive translational study plan.

NineSigma, representing a Japanese leading pharmaceutical company, seeks drug discovery projects which make use of any of the following drug discovery underlying technologies and which are in a hit discovery stage. It is preferable that the research has already started; however, proposals are welcome also from an organization with plans to start a specific project in the future. The client aims to build a drug discovery platform, which is globally competitive, through collaboration with partners. The client can provide opportunities, depending on the R&D stage and the business plan of partners, and hopes not only to foster joint research and development, but also to maximize outcome creation by licensing, support with budget, etc. to support improvement of underlying technology.

This Funding Opportunity Announcement (FOA) encourages applications for Countermeasures Against Chemical Threats (CounterACT) exploratory/developmental translational research (R21). The mission of the CounterACT program is to foster and support research and development of new and improved therapeutics to mitigate the health effects of chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pesticides, and pharmaceutical-based agents. The scope of the research includes basic toxicological research on the chemical threat for the purpose of target and therapeutic hit identification, hit validation, lead optimization, and demonstration of in vivo ADME/Tox and efficacy. Projects supported by this FOA are expected to generate preliminary data that would facilitate the development of competitive applications for more extensive support from the NIH CounterACT Cooperative Agreement programs or other related initiatives.

This Funding Opportunity Announcement (FOA) encourages applications for Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54s). The mission of the CounterACT program is to foster and support research and development of new and improved therapeutics for chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pharmaceutical-based agents, and pesticides. The scope of the research includes target and candidate identification and characterization, through candidate optimization and demonstration of in vivo efficacy consistent with the product's intended use in humans. For applicants submitting U54 renewal applications, research under this FOA should culminate in an optimized lead compound ready for advanced development. The Centers will contain at least three research projects supported by an administrative core, up to three optional scientific cores, and a research education core. Each research project must include milestones that create discrete go or no-go decision points in a progressive translational study plan.

This Funding Opportunity Announcement (FOA) encourages applications for Countermeasures against Chemical Threats (CounterACT) Research Centers of Excellence (U54s). The mission of the CounterACT program is to foster and support research and development of new and improved therapeutics for chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pharmaceutical-based agents, and pesticides. The scope of the research includes target and candidate identification and characterization, through candidate optimization and demonstration of in vivo efficacy consistent with the product's intended use in humans. For applicants submitting U54 renewal applications, research under this FOA should culminate in an optimized lead compound ready for advanced development. The Centers will contain at least three research projects supported by an administrative core, up to three optional scientific cores, and a research education core. Each research project must include milestones that create discrete go or no-go decision points in a progressive translational study plan.

The Process Separations program is part of the Chemical Process Systems cluster, which includes also 1) Catalysis; 2) Process Systems, Reaction Engineering, and Molecular Thermodynamics; and 3) Energy for Sustainability. The Process Separations program supports research focused on novel methods and materials for separation processes, such as those central to the chemical, biochemical, bioprocessing, materials, energy, and pharmaceutical industries. A fundamental understanding of the interfacial, transport, and thermodynamic behavior of multiphase chemical systems as well as quantitative descriptions of processing characteristics in the process-oriented industries is critical for efficient resource management and effective environmental protection. The program encourages proposals that address long standing challenges and emerging research areas and technologies, have a high degree of interdisciplinary work coupled with the generation of fundamental knowledge, and the integration of education and research. Research topics of particular interest include fundamental molecular-level work on: Design of scalable mass separating agents and/or a mechanistic understanding of the interfacial thermodynamics and transport phenomena that relate to purification of gases, chemicals, or water

The Molecular Separations program is part of the Chemical Process Systems cluster, which also includes 1) Catalysis; 2) Electrochemical Systems; and 3) Process Systems, Reaction Engineering, and Molecular Thermodynamics. The Molecular Separations program supports research focused on novel methods and materials for separation processes, such as those central to the chemical, biochemical, bioprocessing, materials, energy, and pharmaceutical industries. A fundamental understanding of the interfacial, transport, and thermodynamic behavior of multiphase chemical systems as well as quantitative descriptions of processing characteristics in the process-oriented industries is critical for efficient resource management and effective environmental protection. The program encourages proposals that address long standing challenges and emerging research areas and technologies, have a high degree of interdisciplinary work coupled with the generation of fundamental knowledge, and the integration of education and research. Research topics of particular interest include fundamental, molecular-level work.

Currently, the drugs are designed in such a way that the active pharmaceutical ingredient (API) is immediately released in the stomach and absorbed in the bloodstream, rapidly relieving the patient from his/her pain (left-hand side). In case multiple doses are taken all at once, a (potentially toxic) supratherapeutic amount of API immediately gets into the user's bloodstream (center). This amount is illicitly used to induce euphoria and could be potentially toxic. Grünenthal's intention is to design a drug formulation that guarantees the API's release profile in case of proper therapeutical usage. However, in case multiple drug units are taken, the release of API, that is available for absorption (right-hand side), will be limited or, at least, decreased to avoid overdosing.

The purpose of this funding opportunity is to conduct activities to promote and support vaccination services within the pharmacy setting. Activities include, but are not limited to: - Education/Outreach to pharmacists about current pediatric, adolescent, and adult immunization recommendations and proper vaccine administration - Facilitation of communication and exchange of information between pharmacists and providers and public health programs -Quality Improvement efforts -Improved immunization documentation through use of immunization information systems and data sharing -Coordination with public health preparedness and immunization programs to establish formalized agreements for pandemic vaccine program readiness and response By the end of the project, the awardee is expected to disseminate and promote best practices/successes to a national audience of healthcare providers, including both pharmacists and other healthcare providers.